{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infiltrating+Bladder+Urothelial+Carcinoma",
    "query": {
      "condition": "Infiltrating Bladder Urothelial Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infiltrating+Bladder+Urothelial+Carcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:54:16.088Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02688348",
      "title": "Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infiltrating Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-04-22",
      "completion_date": "2019-02-28",
      "has_results": false,
      "last_update_posted_date": "2020-07-24",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02688348"
    },
    {
      "nct_id": "NCT03609216",
      "title": "Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infiltrating Bladder Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma",
        "Stage III Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Radical Cystectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemoradiotherapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 237,
      "start_date": "2018-12-10",
      "completion_date": "2029-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 424,
      "location_summary": "Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03609216"
    },
    {
      "nct_id": "NCT02944357",
      "title": "Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infiltrating Bladder Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma",
        "Stage III Bladder Urothelial Carcinoma",
        "Stage IV Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Radical Cystectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Tumor Cell-Derived Vaccine Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-11",
      "completion_date": "2017-09-05",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02944357"
    },
    {
      "nct_id": "NCT03430687",
      "title": "Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage I Bladder Urothelial Carcinoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Talimogene Laherparepvec",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-06-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03430687"
    },
    {
      "nct_id": "NCT06605404",
      "title": "Pan-tumor MRD Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma",
        "Esophageal Cancer",
        "Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma",
        "Melanoma (Skin Cancer)",
        "NSCLC (Non-small Cell Lung Cancer)",
        "Pancreatic (Exocrine Only)",
        "Mix of Solid Tumors (MOST)"
      ],
      "interventions": [
        {
          "name": "blood and tissue samples",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "blood and tissue samples",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Paradigm Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1350,
      "start_date": "2025-01-08",
      "completion_date": "2032-04",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Maumee, Ohio",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Maumee",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06605404"
    },
    {
      "nct_id": "NCT03912818",
      "title": "Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Adenocarcinoma",
        "Bladder Mixed Adenocarcinoma",
        "Bladder Squamous Cell Carcinoma",
        "Bladder Urothelial Carcinoma",
        "Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant",
        "Infiltrating Bladder Urothelial Carcinoma With Giant Cells",
        "Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation",
        "Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation",
        "Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Nested Variant",
        "Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cystectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2019-04-10",
      "completion_date": "2022-08-11",
      "has_results": true,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03912818"
    },
    {
      "nct_id": "NCT05833867",
      "title": "Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Localized Muscle Invasive Bladder Urothelial Carcinoma",
        "Muscle-Invasive Bladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sacituzumab govitecan",
          "type": "DRUG"
        },
        {
          "name": "Adaptive Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Shilpa Gupta, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-04-01",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05833867"
    },
    {
      "nct_id": "NCT05483868",
      "title": "A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-muscle-invasive Bladder Cancer",
        "NMIBC",
        "Non-Muscle Invasive Bladder Carcinoma",
        "Non-Muscle Invasive Bladder Neoplasms",
        "Non-Muscle Invasive Bladder Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "AU-011",
          "type": "DRUG"
        },
        {
          "name": "AU-011 in Combination with Medical Laser Adminstration",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "AU-011 in Combination with Medical Laser Administration",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Aura Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2022-09-26",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Santa Monica, California + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05483868"
    },
    {
      "nct_id": "NCT05700227",
      "title": "Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Daily Adaptive External Beam Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Varian, a Siemens Healthineers Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2023-02-02",
      "completion_date": "2024-05-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05700227"
    },
    {
      "nct_id": "NCT06809140",
      "title": "Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Enfortumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matthew Galsky",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2025-04-07",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-05-22T04:54:16.088Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Indianapolis, Indiana • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06809140"
    }
  ]
}